Dr. Xin has over 20 years of experience developing novel oncology therapies, including small molecules, therapeutic antibodies, antibody-drug conjugates, and immunotherapies. He was previously the SVP and head of clinical development at Turning Point Therapeutics, where he led early and late-stage clinical programs for selective small molecule inhibitors for cancer treatment. He has also served in senior leadership roles in oncology clinical development at Pfizer and Genentech/Roche. He received his M.D. from Zhejiang University School of Medicine and Ph.D. in Cell and Molecular Physiology from the University of North Carolina.